Verona Pharma’s Post

The #FDAApproval of the first inhaled product with a novel mechanism of action for the maintenance treatment of #COPD in over 20 years represents an important advancement for the COPD community.   Thank you to all those involved in our clinical trials, and the Verona team for their support, participation and collaboration!    More: https://bit.ly/4bnUSxt  

#Bronchiectasis is a chronic condition affecting approx. 370,000 adults in the US, where the lung’s bronchi become permanently damaged. On #WorldBronchiectasisDay, we are raising awareness for non-cystic fibrosis bronchiectasis (NCFB), a disease with no FDA-approved drugs specifically for NCFB. Verona’s investigational drug #ensifentrine is currently in Phase 2 clinical studies for the treatment of NCFB. Learn more about this focus area: https://bit.ly/3z3gVvX

The recent #FDAApproval of our novel drug marks an important milestone for Verona Pharma and patients with #COPD in the US. Hear from our leaders and other industry experts on the impact this approval could have on disease management.

Today, at 8:30 a.m. EDT / 1:30 p.m. BST we will host an investor webcast to discuss the US #FDAApproval of Ohtuvayre™ (ensifentrine).     Tune in here: https://bit.ly/4bnUSxt 

BREAKING NEWS: Today, the US FDA approved our drug for the maintenance treatment of #COPD in adults, making it the first inhaled product with a novel mechanism of action for this indication in over 20 years.    Learn more: https://bit.ly/4bnUSxt     #FDAApproval 

Approximately 16 million people in the US are diagnosed with #COPD and cases of COPD are expected to increase worldwide due to exposure to smoke, pollution and other inhaled irritants. Our investigational drug, #ensifentrine, is under FDA review for the maintenance treatment of COPD with a target action date of June 26, 2024. Learn more: https://bit.ly/4banyd9

We are honored to be shortlisted for the European Mediscience Awards 2024, recognizing our work in the ‘Best Communication’ category. Thank you for the recognition of our communications efforts as we work to increase awareness and understanding of our investigational drug for #COPD, #ensifentrine. #EMA24

#COPD medications can be delivered in many different forms, including nebulizers, pills and inhalers. Our investigational drug, #ensifentrine, is delivered directly into the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination. Administration via nebulizer provides a targeted impact. Learn more: https://bit.ly/3PmwDaB